Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dipyridamole for hyperphosphaturia-associated kidney disease or stone disease
MOH_2025-01-08_013217Phase 2Not yet recruiting
- Sponsor
- איתי פטאל
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dipyridamole in hyperphosphaturia, Dent disease, chronic kidney disease (CKD) and 1 more, sponsored by איתי פטאל. Primary endpoint: Change in urinary phosphate excretion. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
dipyridamole
03
Conditions
hyperphosphaturiaDent diseasechronic kidney disease (CKD)nephrolithiasis
Beyond the preview
Go deeper on MOH_2025-01-08_013217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-01-08_013217.